Structure Therapeutics (NASDAQ:GPCR) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Structure Therapeutics (NASDAQ:GPCR) had its price target increased by JPMorgan Chase & Co. from $65.00 to $105.00 in a research report issued on Thursday,Benzinga reports. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price points to a potential upside of 15.05% from the stock’s previous close.

Several other equities analysts have also recently weighed in on GPCR. Wall Street Zen upgraded shares of Structure Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, December 13th. Zacks Research cut Structure Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Friday, October 17th. Guggenheim raised their price target on shares of Structure Therapeutics from $90.00 to $140.00 and gave the stock a “buy” rating in a research note on Tuesday. The Goldman Sachs Group set a $102.00 price objective on Structure Therapeutics in a research note on Monday. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of Structure Therapeutics in a report on Tuesday, October 28th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Structure Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $104.45.

Structure Therapeutics Stock Down 2.7%

Structure Therapeutics stock traded down $2.53 during mid-day trading on Thursday, hitting $91.27. The company’s stock had a trading volume of 564,225 shares, compared to its average volume of 1,383,625. Structure Therapeutics has a twelve month low of $13.22 and a twelve month high of $94.90. The stock’s fifty day moving average price is $58.68 and its two-hundred day moving average price is $35.63. The stock has a market capitalization of $5.54 billion, a P/E ratio of -74.60 and a beta of -2.05.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Thursday, November 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.01). Equities analysts expect that Structure Therapeutics will post -0.82 earnings per share for the current year.

Institutional Investors Weigh In On Structure Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Ameriprise Financial Inc. boosted its position in Structure Therapeutics by 7.2% in the second quarter. Ameriprise Financial Inc. now owns 1,588,198 shares of the company’s stock valued at $32,939,000 after buying an additional 106,389 shares in the last quarter. Casdin Capital LLC increased its holdings in Structure Therapeutics by 26.9% in the 3rd quarter. Casdin Capital LLC now owns 1,555,000 shares of the company’s stock worth $43,540,000 after purchasing an additional 330,000 shares in the last quarter. Millennium Management LLC boosted its stake in shares of Structure Therapeutics by 4.5% during the third quarter. Millennium Management LLC now owns 1,274,551 shares of the company’s stock valued at $35,687,000 after purchasing an additional 54,496 shares in the last quarter. Orbimed Advisors LLC grew its holdings in shares of Structure Therapeutics by 49.5% during the second quarter. Orbimed Advisors LLC now owns 1,199,300 shares of the company’s stock worth $24,873,000 after purchasing an additional 397,272 shares during the last quarter. Finally, Franklin Resources Inc. lifted its holdings in Structure Therapeutics by 0.5% in the third quarter. Franklin Resources Inc. now owns 745,734 shares of the company’s stock valued at $20,881,000 after buying an additional 3,951 shares during the period. 91.78% of the stock is currently owned by institutional investors and hedge funds.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.